Dawn Svoronos - 17 Jun 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Director
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2021
Net transactions value
-$58,793
Form type
4
Filing time
21 Jun 2021, 16:31:30 UTC
Previous filing
11 Jun 2021
Next filing
11 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +3,037 +135% 5,293 17 Jun 2021 Direct F1
transaction GBT Common Stock Sale $58,793 -1,609 -30% $36.54 3,684 18 Jun 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -3,037 -100% $0.000000* 0 17 Jun 2021 Common Stock 3,037 Direct F1, F3
transaction GBT Stock Option (Right to Buy) Award $0 +5,600 $0.000000 5,600 17 Jun 2021 Common Stock 5,600 $37.09 Direct F4
transaction GBT Restricted Stock Units Award $0 +3,600 $0.000000 3,600 17 Jun 2021 Common Stock 3,600 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2021 to cover the Reporting Person's tax obligations in connection with the vesting of 3,037 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The RSUs vested in a single installment on June 17, 2021.
F4 The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
F5 The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).

Remarks:

EXHIBIT 24: Power of Attorney